Table 3.

Correlation analyses of variables and phosphorylated α-synuclein positivity in iRBD patients

Variables	ρ	P
Clinical features analysis (Bonferroni α = 0.007)
Duration of illness	−0.03	0.89
Antidepressant use	−0.11	0.59
MDS-UPDRS III	0.05	0.80
UMSARS Part 1	0.12	0.58
UMSARS Part 2	−0.34	0.11
MoCA	0.23	0.28
UPSIT	−0.23	0.28
Quality of life and symptom analysis (Bonferroni α = 0.003)
ESS	0.01	0.96
Shrag QoL motor	0.01	0.97
Shrag QoL nonmotor	0.17	−0.04
Shrag QoL mood	0.10	0.66
Shrag QoL total score	0.10	0.66
COMPASS-31 orthostatic	0.18	0.39
COMPASS-31 vasomotor	−0.05	0.81
COMPASS-31 secretomotor	0.46	0.02
COMPASS-31 gastrointestinal	0.02	0.93
COMPASS-31 bladder	−0.09	0.66
COMPASS-31 pupillomotor	0.12	0.58
COMPASS-31 total score	0.17	0.41
OHQ total score	0.11	0.61
Autonomic testing analysis (Bonferroni α = 0.004)
E:I ratio	−0.35	0.08
Valsalva BP baseline	−0.11	0.60
Valsalva P2 BP recovery	−0.01	0.98
Valsalva P4 overshoot	−0.31	0.14
Tilt ΔSBP	−0.10	0.64
QSART volume forearm	−0.17	0.44
QSART volume proximal leg	−0.04	0.87
QSART volume distal leg	−0.05	0.81
QSART volume foot	0.09	0.68
CASS sudomotor	0.21	0.32
CASS cardiovagal	0.40	0.06
CASS adrenergic	0.60	0.002
CASS total	0.60	0.002

Correlations that remain significant after Bonferroni correction are bolded and italicized.

iRBD, isolated REM sleep behavior disorder; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; UMSARS, Unified Multiple System Atrophy Rating Scale; MoCA, Montreal Cognitive Assessment; CASS, Composite Autonomic Severity Scale; UPSIT, University of Pittsburg Smell Identification Test; COMPASS, Composite Autonomic Symptom Scale-31; OHQ, Orthostatic Hypotension Questionnaire; SCOPA-AUT, Scale for Outcomes in PD-Autonomic.